Latest From Reed Miller
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
In this week’s podcast, Medtech Insight's managing editor Marion Webb discusses Guardant Health’s launch of a new liquid biopsy test to detect early-stage colorectal cancer. Deputy editor Reed Miller discusses Canadian-based Neovasc’s recent funding and what it could mean for its Reducer transcatheter technology. UK-based reporter Barnaby Pickering gives an overview of the fast-growing insulin pump market.
Shockwave Medical received a FDA premarket approval for its C2 coronary intravascular lithotripsy-based calcification remedy and announced its 2020 results, in line with expectations.
The addition of the Arizona-based sequencing lab builds on Exact’s recent license of the TARDIS liquid biopsy technology from TGen.